secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001823239-25-000028
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai postpones Q4/FY2024 earnings, cites material weakness in revenue recognition and potential goodwill impairment
--------------------------------------------------------------------------------

- Earnings release and call postponed; 10-K filing delayed until March 18, 2025.
- Preliminary FY2024 revenue near midpoint of $255M-$265M guidance.
- Additional time needed for goodwill impairment assessment related to Alphazyme LLC acquisition.
- Revenue recognition error for ~$3.9M shipment recorded in wrong quarter; no full-year impact.
- Assessing effectiveness of internal controls; material weakness in revenue recognition identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000028/0001823239-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000028/mrvi-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001823239-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer